Authors

Latest:

Dr. Murthy on De-Escalation Strategies in HER2-Positive Breast Cancer

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses de-escalation strategies for patients with HER2-positive breast cancer.

Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center

Latest:

Expanding Treatment Options for HER2+ Breast Cancer

Rashmi Murthy, MD, MD Anderson Cancer Center

Ravi A. Chandra, MD, PhD

Latest:

Recognizing the Role of Bias in Patient Decision Making

Doctors are taught to think through medical decisions by listing a series of options, weighing the risks and benefits of each, and ultimately concluding on the superior option. This comparative maximization approach is drilled into us as medical students and residents.

Ravi Salgia, MD, PhD

Latest:

Dr Salgia on Biomarker-Driven Therapies of Interest for Second-Line SCLC

Ravi Salgia, MD, PhD, highlights biomarker-driven strategies in development for second-line small cell lung cancer management.

Ravi Vij, MD

Latest:

Dr. Vij on the Integration of Selinexor in Relapsed/Refractory Multiple Myeloma

Ravi Vij, MD, MBA, discusses the integration of selinexor into the relapsed/refractory multiple myeloma armamentarium.

Ravi Vij, MD, MBA

Latest:

Dr. Vij on the Potential of CELMoDs in Relapsed/Refractory Multiple Myeloma

Ravi Vij, MD, MBA, discusses the potential of cereblon E3 ligase modulators in relapsed/refractory multiple myeloma.

Ravindra Uppaluri, MD, PhD

Latest:

Dr Uppaluri on the Implications of the FDA Approval of Perioperative Pembrolizumab in Resectable, Locally Advanced HNSCC

Ravindra Uppaluri, MD, PhD, discusses the FDA approval of pembrolizumab in the neoadjuvant and adjuvant setting for resectable, locally advanced HNSCC.

Raymond U. Osarogiagbon, MD, FACP

Latest:

Dr. Osarogiagbon on the Effects of the COVID-19 Pandemic on Lung Cancer Screening

Raymond U. Osarogiagbon, MD, FACP, discusses the long-term effects of the COVID-19 pandemic on lung cancer screenings.

Rebecca Arend, MD

Latest:

Dr. Arend Discusses Targets in Endometrial Cancer

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses targeted therapies in endometrial cancer.

Rebecca C. Arend, MD

Latest:

FDA Approval of Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

A brief review of the FDA approval and implications of tisotumab vedotin in patients with recurrent or metastatic cervical cancer.

Rebecca Clark-Snow, RN, BSN, OCN, University of Kansas Cancer Center

Rebecca Dent, MD, MSc, FRCP

Rebecca Dent, MD, MSc, FRCP, is deputy chief executive officer (clinical) and a senior consultant at the National Cancer Centre Singapore

Latest:

Dr Dent on the Potential Role of Dato-DXd for Immunotherapy-Ineligible TNBC

Rebecca Dent, MD, MSc, FRCP, discussed the future implications of data with first-line Dato-DXd in locally recurrent inoperable or metastatic TNBC.

Rebecca Feldman, PhD

Latest:

Rebecca Feldman on Oncogenic Role of Caveolin-1 in Breast Cancer

Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1 as potentially having an oncogenic role in breast cancer.

Rebecca Kristeleit, BSc, PhD

Latest:

Dr Kristeleit on the Implications of Long-Term Data With Rucaparib in Advanced Ovarian Cancer

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.

Rebecca Kronk, PhD, CRNP, MSN, Duquesne

Rebecca L. Aft, MD, PhD

Latest:

Dr. Aft on Bisphosphonates for Breast Cancer

Rebecca L. Aft, MD, PhD, professor of surgery at the Washington University School of Medicine in St. Louis and a physician at Siteman Cancer Center, discusses the use of bisphosphonates for patients with breast cancer.

Rebecca L. Olin, MD, MSCE

Latest:

Dr. Olin on the Rationale to Evaluate Menin Inhibitors in AML

Rebecca L. Olin, MD, MSCE, discusses the rationale to evaluate menin inhibitors in acute myeloid leukemia.

Rebecca M. Minter, MD

Latest:

Prevention Program Targets Pancreatic Cancer Before It Gains a Foothold

Pancreatic cancer is currently the fourth-leading cause of cancer death in the United States, with a 5-year survival rate of approximately 8%.

Rebecca S. Sippel, MD

Latest:

Dr. Sippel Explains Thyroid Cancer Risk Factors

Rebecca S. Sippel, MD, from University of Wisconsin, explains the need for added screening for those at high-risk of developing thyroid cancer.